• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    9/27/21 4:19:25 PM ET
    $SRNG
    Get the next $SRNG alert in real time by email
    SC 13G 1 p21-2216sc13g.htm GINKGO BIOWORKS HOLDINGS, INC.
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
     

    GINKGO BIOWORKS HOLDINGS, INC.

    (Name of Issuer)
     

    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    37611X100

    (CUSIP Number)
     

    September 16, 2021

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No.  37611X100

    13GPage 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    SENATOR INVESTMENT GROUP LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    80,153,273

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    80,153,273

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    80,153,273

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.03%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

    CUSIP No.  37611X100

    13GPage 3 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

    DOUGLAS SILVERMAN

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    UNITED STATES

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    80,153,273

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    80,153,273

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    80,153,273

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.03%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No.  37611X100

    13GPage 4 of 9 Pages

     

     

    Item 1(a). NAME OF ISSUER
       
      GINKGO BIOWORKS HOLDINGS, INC. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
     

    27 Drydock Avenue

    8th Floor

    Boston , MA 02210

       
    Item 2 (a). NAME OF PERSON FILING
       
      Senator Investment Group LP (“Senator Investment Group”) serves as investment manager to various investment funds (collectively, the “Funds”), and as such, has investment discretion with respect to the Funds. Douglas Silverman (“Mr. Silverman,” together with Senator Investment Group, the “Reporting Persons”) has control of a Delaware limited liability company that may be deemed to control Senator Investment Group.
       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock (as defined below) reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The principal office of each of the Reporting Persons is:
       
      c/o Senator Investment Group LP
      510 Madison Avenue
      28th Floor
      New York, NY 10022

     

    Item 2(c). CITIZENSHIP
       
      Senator Investment Group LP is a Delaware limited partnership. Mr. Silverman is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Class A common stock, par value $0.0001 per share

     

    Item 2(e). CUSIP NUMBER
       
      37611X100

     

     

    CUSIP No.  37611X100

    13GPage 5 of 9 Pages

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                  

     

    Item 4. OWNERSHIP

     

      Senator Investment Group, LP
       
             (a)    Amount of beneficially owned: 80,153,273.
       
             (b)    Percent of class: 6.03%.  The percentages used in this Schedule 13G are calculated based upon 1,330,072,374 shares of Class A Common Stock reported to be outstanding immediately after giving effect to the issuer's business combination, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 20, 2021.
       
             (c)    Number of shares as to which such person has:

     

                      (i) Sole power to vote or to direct the vote:  

     

          0

     

     

    CUSIP No.  37611X100

    13GPage 6 of 9 Pages

     

     

                      (ii) Shared power to vote or to direct the vote

     

          80,153,273

     

                      (iii) Sole power to dispose or to direct the disposition of

     

          0

     

                      (iv) Shared power to dispose or to direct the disposition of

     

          80,153,273

     

      Mr. Silverman
       
             (a)    Amount of beneficially owned: 80,153,273.
       
             (b)    Percent of class: 6.03%.
       
             (c)    Number of shares as to which such person has:

     

                      (i) Sole power to vote or to direct the vote:  

     

          0

     

                      (ii) Shared power to vote or to direct the vote

     

          80,153,273

     

                      (iii) Sole power to dispose or to direct the disposition of

     

          0

     

                      (iv) Shared power to dispose or to direct the disposition of

     

          80,153,273

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      The partners and shareholders of the Funds have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities reported herein held by the Funds in accordance with their respective ownership interests in the Funds.

     

     

    CUSIP No.  37611X100

    13GPage 7 of 9 Pages

     

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION

     

      By signing below each of the Reporting Persons certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

    CUSIP No.  37611X100

    13GPage 8 of 9 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATE: as of September 27, 2021

     

      SENATOR INVESTMENT GROUP LP
       
       
      /s/ Evan Gartenlaub
     

    Name: Evan Gartenlaub

    Title: General Counsel

       
       
      /s/ Evan Gartenlaub as Attorney-in-Fact*
      DOUGLAS SILVERMAN

     

     

     

    * Pursuant to a Power of Attorney attached to the Schedule 13G filed by the Reporting Persons on April 24, 2013.

     

     

    CUSIP No.  37611X100

    13GPage 9 of 9 Pages

     

    Exhibit 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATE: as of September 27, 2021

     

      SENATOR INVESTMENT GROUP LP
       
       
      /s/ Evan Gartenlaub
     

    Name: Evan Gartenlaub

    Title: General Counsel

       
       
      /s/ Evan Gartenlaub as Attorney-in-Fact*
      DOUGLAS SILVERMAN

     

     

     

    * Pursuant to a Power of Attorney attached to the Schedule 13G filed by the Reporting Persons on April 24, 2013.

     

    Get the next $SRNG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRNG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds

    Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021 Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021 $1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction. Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors. Business combination with Ginkgo approved by Soaring Eagl

    9/14/21 9:13:00 AM ET
    $SRNG

    Africa CDC and Ginkgo Bioworks Announce Collaboration to Strengthen Laboratory Network Capacity Across African Union Member States

    BOSTON and ADDIS ABABA, Ethiopia, Sept. 14, 2021 /PRNewswire/ -- The Africa Centres for Disease Control and Prevention (Africa CDC), a specialized technical institution of the African Union, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to bolster the laboratory network capacity for African Union Member States. The partnership is aimed at supporting the continent's public health institutions with appropriate tools, training, and data infrastructure to leverage critical genomic sequencing technologies that will be implemented through Africa CDC Institute for Pathogen Genomics (IPG) and Ginkgo Bioworks.  Gin

    9/14/21 7:58:00 AM ET
    $SRNG

    Concentric by Ginkgo Stands Ready to Continue Fighting Pandemic, Providing Biosecurity and COVID Testing Nationwide to Schools, Workplaces, and Other Congregate Settings

    BOSTON, Sept. 10, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced its readiness to continue scaling support for COVID testing in congregate settings in response to new emergency standards and recommendations issued by the Biden-Harris Administration. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Last year, Ginkgo launched Concentric by Ginkgo, its public health and biosecurity initiative, to provide a response to the COVID-19 pandemic. Since then, Conc

    9/10/21 3:00:00 PM ET
    $SRNG

    $SRNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Cascade Investment, L.L.C. claimed ownership of 151,865,481 units of Class A Common Stock

    3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/24/21 4:24:22 PM ET
    $SRNG

    SEC Form 3: New insider Viking Global Investors Lp claimed ownership of 339,055,144 units of Class A Common Stock

    3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/23/21 4:11:12 PM ET
    $SRNG

    SEC Form 4: Eagle Equity Partners Iii, Llc returned 11,534,052 units of Class A Common Stock to the company, decreasing direct ownership by 27% to 31,590,948 units

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/22/21 9:57:03 PM ET
    $SRNG

    $SRNG
    SEC Filings

    View All

    SEC Form EFFECT filed by Soaring Eagle Acquisition Corp.

    EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/21/21 12:15:16 AM ET
    $SRNG

    SEC Form 424B3 filed by Soaring Eagle Acquisition Corp.

    424B3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/20/21 5:24:23 PM ET
    $SRNG

    Soaring Eagle Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

    8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/20/21 5:19:07 PM ET
    $SRNG

    $SRNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Soaring Eagle Acquisition Corp. (Amendment)

    SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    10/1/21 5:02:37 PM ET
    $SRNG

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/28/21 4:31:04 PM ET
    $SRNG

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/27/21 5:29:26 PM ET
    $SRNG

    $SRNG
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Announces Date of First Half 2021 Results Presentation

    BOSTON, Aug. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo"), which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET. The presentation will include an overview of first half performance, recent updates, and a discussion on Ginkgo's business model and outlook. The presentation details and registration link will be available on Ginkgo's investor relation

    8/9/21 7:00:00 AM ET
    $SRNG